Experience with sunitinib in the treatment of metastatic renal cell carcinoma
about
Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementCentral and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsPharmacotherapies for renal cell carcinoma in Japan.Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.Thyroid Hormone, Cancer, and Apoptosis.Acute Pancreatitis Related to a Chemotherapy DrugLysosome-associated membrane protein 2 (LAMP-2) expression induced by miR-194-5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells.Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma.Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
P2860
Q26801279-58DBED96-8906-4CFE-8D38-24A8CC6643A3Q33419600-A1544716-1E7A-45B6-AE79-3E8ACBB0106CQ33691188-F970E139-774F-474A-A303-E5BC10625EF1Q33698419-12D3453D-75B6-4C66-975A-A7CB8225C104Q38668274-996F47A1-2062-485D-B396-7FCEEB4CDA2AQ38817505-0F6EB22B-84AD-448F-B372-67DE87284A0BQ38878225-5FA2F739-092D-491A-92A1-343F5500AF98Q42182271-C6F0039D-E36B-4CBC-8EDC-7D4B9A6B34A3Q49335182-22D8B70C-73E2-4B5D-B69C-81CD9541212DQ52571238-30701F8D-B372-4A83-BA42-69F570C8CE5AQ53113774-E894C13D-4564-47CE-A7DE-AC284F8E926BQ54298665-B5C795EB-62F9-477D-A463-ADD137AEC5EEQ55066009-9402AB02-79D3-4468-9867-72EF10DF67CCQ58790703-F0DFB30C-D708-4E26-82E8-59C372F6DA01
P2860
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
@ast
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
@en
type
label
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
@ast
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
@en
prefLabel
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
@ast
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
@en
P2093
P2860
P356
P1476
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
@en
P2093
Alain Ravaud
James Larkin
Manuela Schmidinger
P2860
P304
P356
10.1177/1756287212454933
P577
2012-10-01T00:00:00Z